Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.

PURPOSE To evaluate neoadjuvant capecitabine/oxaliplatin before chemoradiotherapy (CRT) and total mesorectal excision (TME) in newly diagnosed patients with magnetic resonance imaging (MRI) -defined poor-risk rectal cancer. PATIENTS AND METHODS MRI criteria for poor-risk rectal cancer were tumors within 1 mm of mesorectal fascia (ie, circumferential resection margin threatened), T3 tumors at or below levators, tumors extending > or = 5 mm into perirectal fat, T4 tumors, and T1-4N2 tumors. Patients received 12 weeks of neoadjuvant capecitabine/oxaliplatin followed by concomitant capecitabine and radiotherapy. TME was planned 6 weeks after CRT. Postoperatively, patients received another 12 weeks of capecitabine. RESULTS Between November 2001 and August 2004, 77 eligible patients were recruited. After neoadjuvant capecitabine/oxaliplatin, the radiologic response rate was 88%. In addition, 86% of patients had symptomatic responses in a median of 32 days (ie, just over one cycle of capecitabine/oxaliplatin). After CRT, the tumor response rate was increased to 97%. Three patients remained inoperable. Sixty-seven patients proceeded to TME, and all but one patient had R0 resection. Pathologic complete response was observed in 16 patients (24%; 95% CI, 14% to 36%), and in an additional 32 patients (48%), only microscopic tumor foci were found on surgical specimens. Four deaths occurred during neoadjuvant capecitabine/oxaliplatin therapy as a result of pulmonary embolism, ischemic heart disease, sudden death with history of chest pain, and neutropenic colitis. CONCLUSION Capecitabine/oxaliplatin before synchronous CRT and TME results in substantial tumor regression, rapid symptomatic response, and achievement of R0 resection.

[1]  Rainer Fietkau,et al.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Sang‐wook Lee,et al.  Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[3]  E. Urso,et al.  A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Norman,et al.  The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). , 2005, European journal of cancer.

[5]  P. Quirke,et al.  The Modern Abdominoperineal Excision: The Next Challenge After Total Mesorectal Excision , 2005, Annals of surgery.

[6]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[7]  R. Glynne-Jones,et al.  Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). , 2005 .

[8]  L. Collette,et al.  Preoperative radiation (Preop RT) in rectal cancer: Effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial , 2005 .

[9]  N. Wolmark,et al.  A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .

[10]  R. Greil,et al.  Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis , 2005 .

[11]  G Brown,et al.  Techniques and trouble-shooting in high spatial resolution thin slice MRI for rectal cancer. , 2005, The British journal of radiology.

[12]  S. Loi,et al.  Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial , 2005, British Journal of Cancer.

[13]  Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. , 2005, Anticancer research.

[14]  S. Miles,et al.  Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Brown,et al.  Preoperative staging of rectal cancer: the MERCURY research project. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[16]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[17]  J. Zalcberg,et al.  A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer , 2004, British Journal of Cancer.

[18]  A. Norman,et al.  Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting , 2004 .

[19]  T. Conroy,et al.  Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial , 2004 .

[20]  J. Debus,et al.  Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Newcombe,et al.  Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.

[22]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[23]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Daniel J Sargent,et al.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Hohenberger,et al.  Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Nagtegaal,et al.  Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. , 2003, International journal of radiation oncology, biology, physics.

[29]  A. Norman,et al.  Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer , 2003, British Journal of Cancer.

[30]  P. Adeleine,et al.  Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R G Newcombe,et al.  Preoperative assessment of prognostic factors in rectal cancer using high‐resolution magnetic resonance imaging , 2003, The British journal of surgery.

[32]  A. Hinke,et al.  Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Barugel,et al.  Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. , 2002, International journal of radiation oncology, biology, physics.

[34]  K. Song,et al.  Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[35]  H. Putter,et al.  Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands , 2002, The British journal of surgery.

[36]  P. Quirke,et al.  Rates of Circumferential Resection Margin Involvement Vary Between Surgeons and Predict Outcomes in Rectal Cancer Surgery , 2002, Annals of surgery.

[37]  I. Nagtegaal,et al.  Circumferential Margin Involvement Is Still an Important Predictor of Local Recurrence in Rectal Carcinoma: Not One Millimeter but Two Millimeters Is the Limit , 2002, The American journal of surgical pathology.

[38]  T. Mala,et al.  Local recurrence after mesorectal excision for rectal cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  O Søreide,et al.  Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer , 2002, The British journal of surgery.

[40]  D J Sargent,et al.  Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.

[42]  P. Romestaing,et al.  Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. A’Hern Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[44]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[45]  K. Havenga,et al.  Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[46]  R. Newcombe,et al.  Rectal carcinoma: thin-section MR imaging for staging in 28 patients. , 1999, Radiology.

[47]  J. Macfarlane,et al.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. , 1998, Archives of surgery.

[48]  P. Quirke,et al.  Role of circumferential margin involvement in the local recurrence of rectal cancer , 1994, The Lancet.

[49]  P. Quirke,et al.  LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTION Histopathological Study of Lateral Tumour Spread and Surgical Excision , 1986, The Lancet.

[50]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .